Accelerate to discover

Back to filter

Related topics

IncuCyte webinar: high throughput approach to developing T- Cell immunotherapies

Sartorius

Jun 17, 2019

Immunotherapy for cancers involves artificially prompting the immune system to treat cancer. Many cancer cells have...

Low-dose imaging in a new preclinical total-body PET/CT scanner

Bruker Biospin

Jun 12, 2019

Ionizing radiation constitutes a health risk to imaging scientists and study animals. Both PET and CT produce ionizing...

Fluxion Biosciences and National Cancer Institute cooperate to validate IsoFlux for sequencing

Fluxion Biosciences

Jun 12, 2019

Fluxion with IsoFlux has partnered with the Cleveland Clinic. They are aiming to improve sensitivity by timing the...

New insight into Cas9 off-target activity

LUMICKS

Jun 7, 2019

Scientists at the MRC London Institute of Medical Sciences and AstraZeneca studied how CRISPR-Cas9 differentiates...

Jun 18, 2019

Join the AVANCE Track & Keep your MRI on Track

Bruker Biospin

Jun 4, 2019

Your research depends on the scientific advances that you make with your MRI instrument. Take your instrument and your...

A novel method for isolating high-quality UHMW DNA from animal and human tissues

BioNano Genomics

May 31, 2019

New isolation protocol for isolating high-quality UHMW DNA from 10 mg of freshly frozen or liquid-preserved animal and...

ParaVision 7 software

Bruker Biospin

May 27, 2019

The preclinical MRI software ParaVision 7 delivers unsurpassed image quality and enhanced productivity for both routine...

Jun 18, 2019

HLS-CATCH: Cas-9 assisted gene purification

Sage Science

May 24, 2019

The CATCH process  provides researchers with the most direct access to genes for study. Target regions are defined with...

Show all topics (10)

Morphological and pharmacological in-vitro kinetic angiogenesis assays

Nov 16, 2016

The ADSC/ECFC model yields rapidly forming (<48h) endothelial cell‘cord’structures. In the NHDF/HUVEC slowly forming‘tube-like’structures appear which continue to develop and branch even after 10days in culture. High basal formation was observed in the ADSC/ECFC model, but not in the NHDF/HUVEC model. From immuno-cytochemistry, the ADSCs surrounding the cord network label for PDGFR-β and a-SMA, suggesting apericyte phenotype.The pharmacological effects of growth factors and different pathway inhibitors were largely comparable. Interestingly, established cords and tubes display marked resistance to Avastin (Bevacizumab) compared to developing networks. G-secretase inhibition partially reversed established tubes in ADSC/ECFCs and augmented late state branching in the NHDF/HUVEC model. We conclude that these 2 models exhibit strikingly different morphological, temporal and pharmacological profiles. The resistance of established vascular structures to disruption by Avastin (Bevazicumab) may represent a useful translational paradigm for addressing tumour resistance of anti-VEGF therapies.

Read more

Scientific paper
Application
Product news

Related technologies: Real-time, label free cell analysis

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Sartorius

Essen BioScience (part of Sartorius), is a team of engineers and biologists with deep expertise in cell-based assays. We invent, manufacture, supply and support cell-based assay instrumentation, reagents and protocols.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey